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Objective: The proper treatment of chronic ischemic mitral regurgitation (CIMR) is still under evaluation. The
different role of mitral valve repair (MVr) or mitral valve prosthesis insertion (MVPI) is still not deﬁned.
Methods: From May 2009 to December 2011 167 patients with ejection fraction (EF) ≤40% had MV surgery for
CIMR, MVr in 135 (80.8%) and MVPI in 32 (19.2%). Indication to MVPI was a MV coaptation depth N10 mm. EF
was lower (26 ± 7 vs 32 ± 6, p = 0.0000) in MVPI, whereas MR grade (3.6 ± 0.8 vs 2.7 ± 0.9, p = 0.0000),
left ventricle dimensions (end diastolic, LVEDD, 62 ± 7 vs 57 ± 6 mm, p = 0.0001; end systolic, LVESD, 49 ±
8 vs 44 ± 8 mm, p = 0.0018), systolic pulmonary artery pressure (51 ± 22 vs 41 ± 16 mm Hg, p = 0.0037)
and NYHA Class (3.6 ± 0.5 vs 2.8 ± 0.6, p = 0.0000) were higher.
Results: In-hospital mortality was similar (3.1 vs 3.7%) as well as 3-year survival (86 ± 6 vs 88± 4) and survival
inNYHA Class I/II (80±5 vs 83±4). One hundred thirty nine patients had an echocardiographic evaluation after
aminimumof 4 months (13±8). EF rose signiﬁcantly in both groups (from26±7% to 30±4%, p= 0.0122, and
from 32±6% to 35±8%, p= 0.0018). LVESD reduced signiﬁcantly in both groups (from 49±8 to 43±9mm,
p = 0.0109, and from 44 ± 8 to 41 ± 7 mm, p = 0.0033). MR grade was signiﬁcantly lower in patients who
had MVPI (0.1 ± 0.2 vs 0.3 ± 0.3, p = 0.0011).
Conclusions:With appropriate indications,MVPI is a safe procedurewhich provides similar results toMVrwith
lower MR return, even if addressed to patients with worse preoperative parameters.
© 2014 The Authors. Publishedby Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Surgical treatment of chronic ischemic mitral regurgitation (CIMR)
is nowadays more standardized, as its pathophysiology is better under-
stood. Restrictive mitral valve (MV) annulopasty, proposed by Bolling
et al. [1] is the procedure of choice. Other adjunctive procedures, as
chordal cutting, papillary muscle repositioning, augmentation of
leaﬂets, have been proposed, but their usefulness is still not well dem-
onstrated. The possibility to insert a MV prosthesis in selected cases,
proposed by our group [2], has recently been supported by other studies
[3–6], which report mid and long term results similar to those of MV
repair with lower grade of late MR. The failure rate of restrictive MV
annuloplasty remains one of the weak points of the surgical treatment
of CIMR and it is related to lower survival and worse clinical [7] and
echocardiographic outcome., University of L'Aquila, 76100
quila, L'Aquila, Italy. Tel.: +39
uro).
land Ltd. This is an open access articleWe tried to rationalize MV surgery (repair or prosthesis insertion)
for CIMR correction [2,8,9]. We herein report our more recent experi-
ence in patients with CIMR and ejection fraction (EF) ≤40% to evaluate
if the strict application of that strategy could reproduce and conﬁrm the
results of our previous experiences from which it was generated.
2. Material and methods
From May 2009 till December 2011 167 patients with ejection
fraction (EF) ≤40% underwent MV surgery for CIMR as ﬁrst procedure.
One hundred thirty ﬁve (80.8%) had MV repair (group MVr) and 32
underwent MV prosthesis insertion (group MVPI). Patients in cardio-
genic shock were not included. The Institutional Review Board ap-
proved the research and waived patients' consent.
2.1. Deﬁnition
CIMR is deﬁned as anyMR that is due to excess of tethering of either
or both leaﬂets as a result of misalignment of either or both papillaryunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tion with regional wall abnormalities.
2.2. Preoperative echocardiographic evaluation
MRwas graded following the European Society of Echocardiography
recommendations [10]. MR was deﬁned mainly according to vena
contracta:mild (1+) if b3mm,moderate (2+) if 3 to b5mm,moderate
to severe (3+) from5 to b7mmand severe (4+) if≥7mm. Recurrence
of MR was deﬁned as postoperative MR ≥ 2+. All echocardiographic
measurements followed American Society of Echocardiography and
European Society of Echocardiography guidelines [11]. Table 1 shows
some relevant echocardiographic preoperative characteristics. Tissue
Doppler Imaging S′ (TDI) was used to assess right ventricular (RV) func-
tion. A value of b10 cm/s was the cut point to identify RV dysfunction.
2.3. Surgical indications
All patients with CIMR≥2+were candidates for MV surgery. CIMR
1+was never treated, but in 3 cases,where the systolic septolateral dis-
tance was severely dilated (N32 mm) and/or the coaptation length was
minimal (≤2 mm). A coaptation depth (CD) of 10 mm or less was the
limit for MV repair. If the CDwas N10, the anatomywas not considered
suitable for repair, and a prosthesis was inserted into the MV [2,8,9]. If
the anterior leaﬂet (AL) was short (b25 mm) or excessively tethered,
we respectively augmented or cut the second-order chords [9].
2.4. Surgical technique
After a median sternotomy, the ascending aorta and both venae
cavae were cannulated, the superior vena cava directly. The MV was
approached transseptally through a right atriotomy. The mitral annulus
was reshaped with the SMB40 (Sorin Biomedica SpA, Saluggia, Italy) in
115 patients and with a Physioring (Edwards Lifescience, Irvine, CA,
USA), median #26, in 20 patients. Insertion of a prosthesis inside the
MV was obtained by cutting only a triangle of the AL with the base at
AL insertion and the apex at the midpoint of A2. The remainder of the
AL was pushed toward the annulus with the prosthetic sutures [8].
Any short (b25 mm) AL was disconnected from its insertion, and a
pericardial patch was used to extend its height. The second-order
chords were always cut to provide better mobility of the leaﬂet. WhenTable 1
Clinical and echocardiographic data.
All (n = 167) M
Age (y:mean ± SD) 62 ± 10 63
Female gender (n, %) 39 (23.4) 34
NYHA Class (mean ± SD) 2.9 ± 0.6 2.8
Class II (n, %) 43 (13.5) 43
Class III (n, %) 97 (68.8) 86
Class IV (n, %) 30 (17.7) 9
EuroSCORE (mean ± SD) 7.0 ± 4.9 6.1
Diabetes mellitus (n, %) 119 (71.2) 10
AF (n, %) 22 (13.2) 16
Previous AMI
Anterior (n, %) 55 (32.9) 40
Lateral (n, %) 17 (10.2) 13
Inferior (n, %) 95 (56.9) 82
EF (%:mean ± SD) 31 ± 7 32
LVEDD (mm:mean ± SD) 58 ± 7 57
LVESD (mm:mean ± SD) 45 ± 8 44
Coaptation depth (mm) 8.6 ± 3.1 7.8
MR grade (1–4:mean ± SD) 2.9 ± 1.0 2.7
PAPs (mm Hg:mean ± SD) 43 ± 18 41
TDI (cm/s) 11.6 ± 1.2 11
Legend. MVr, mitral valve repair; MVPI, mitral valve prosthesis insertion; y, year; SD, standard d
infarction; EF, ejection fraction; LVEDD, left ventricular end diastolic diameter: LVESD, left ven
systolic; TDI, Tissue Doppler Imaging.the second-order chords tethered the AL excessively, an aortotomy
was performed, and these chordae were cut to increase the mobility of
the leaﬂet.
Different techniques were used to exclude ventricular scars. In the
case of an inferior scar, an incision parallel to the descending posterior
artery was performed, and the scar was longitudinally excluded with
interrupted U sutures. If the scar was limited to the apex and to the
apical septum, a Dor procedure (purse-string with or without patch)
was used. If the scar involved the septum more than the anterior free
wall, a septal reshaping was performed. The purpose of these proce-
dures was always to rebuild a conical shape.
Tricuspid repair was performed using a 50 mm long band (n = 62)
or a MC3 (n = 13).
2.5. Clinical follow-up
All patients were clinically followed up in our outpatient clinic 3, 6,
and 12 months after surgery and thereafter at yearly intervals. The
most recent information was obtained by telephone interview.
Follow-up was 98% complete. As some patient was living outside the
country, in case of impossibility to contact him, the information at the
last follow-upwere considered if it waswithin the last 6 months, other-
wise the patient was considered lost to follow-up. Mean follow-up time
was 19 ± 9 months.
2.6. Echocardiographic follow-up
Every patient had at least one echocardiographic evaluation at
discharge and 139 patients had a control during the follow-up. Time
from surgery to the last control was 15 ± 8 months.
2.7. End points
The primary end points of this study were clinical and echocardio-
graphic results as a whole and in the two groups were at the basis of
this research.
2.8. Statistical analysis
Results are expressed as mean ± SD. Categorical variables are re-
ported as counts and percentages. Echocardiographic modiﬁcationsVr (n = 135) MVPI (n = 32) p
± 10 62 ± 10 0.6117
(25.2) 5 (15.6) 0.2504
± 0.6 3.6 ± 0.5 0.0000
(31.8) –
(63.7) 11 (34.3) 0.000
(6.7) 21 (65.6)
± 3.9 10.6 ± 6.6 0.0000
0 (74.1) 19 (59.4) 0.0985
(11.8) 6 (18.8) 0.2996
(29.6) 15 (46.9)
(9.6) 4 (12.5) 0.1120
(60.7) 13 (40.6)
± 6 26 ± 7 0.0000
± 6 62 ± 7 0.0001
± 8 49 ± 8 0.0018
± 2.7 12.2 ± 3.3
± 0.9 3.6 ± 0.8 0.0000
± 16 51 ± 22 0.0037
.5 ± 1.1 11.9 ± 1.4 0.0819
eviation; NYHA, New York Heart Association; AF, atrial ﬁbrillation; AMI, acute myocardial
tricular end systolic diameter; MR, mitral regurgitation; PAPs, pulmonary artery pressure
Table 1e
Echocardiographic follow up in patients without SVR.
MVr (n = 85) MVPI (n = 15)
Pre Post p Pre Post p
EF (%:mean ± SD) 33 ± 6 36 ± 8 0.0063 28 ± 5 30 ± 6 0.3298
LVEDD (mm:mean ± SD) 56 ± 6 52 ± 7 0.0001 63 ± 6 56 ± 10 0.0276
LVESD (mm:mean ± SD) 42 ± 7 40 ± 7 0.0643 48 ± 8 45 ± 9 0.3429
MR grade (1–4:mean ± SD) 2.6 ± 1.1 0.4 ± 0.6 0.0000 3.7 ± 0.7 0.1 ± 0.2 0.0000
PAPs (mm Hg:mean ± SD) 38 ± 15 34 ± 11 0.0490 43 ± 17 32 ± 11 0.0445
TDI (cm/s) 11.5 ± 1.2 12.0 ± 1.4 0.0134 11.7 ± 1.5 11.9 ± 0.8 0.6522
Gradient (mm Hg: mean ± SD) – 4 ± 2 – – 5 ± 3 0.1033
Legend.MVr,mitral valve repair;MVPI,mitral valve prosthesis insertion; SD, standarddeviation; EF, ejection fraction; LVEDD, left ventricular enddiastolic diameter; LVESD, left ventricular
end systolic diameter; MR, mitral regurgitation; PAPs, pulmonary artery pressure systolic; TDI, Tissue Doppler Imaging.
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vival was evaluated by the Kaplan–Meier method. A non-parsimonious
multivariatemodel was developed to estimate propensity scores, which
were used as an adjusting variable in the Cox regression models. The
optimal cutoff was determined by receiver operating characteristic
curve analysis. The SPSS software package (SPSS Inc., an IBM Company,
Chicago, Ill) was used.
3. Results
Table 1 shows some preoperative characteristics. Patients who
underwent MVPI had a lower ejection fraction and larger hearts, with
more severe CIMR. Pulmonary pressure was higher, and, by deﬁnition,
coaptation depth was longer in this group. RV function was similar on
both groups, and 10 patients (6.0%), 7 in MVr group and 3 in MVPI
group (p = 0.3691) had some grade of RV dysfunction.
Table 2 shows some surgical details. TV surgery and LV surgical
remodeling were more frequent in MVPI. Other procedures on the MV
were performed globally in 12 patients (7.6%) in MVr group. Only 4
patients (3 in MVr group and 1 in MVPI group) had no coronary artery
bypass grafting. ROC curve analysis showed that the possibility to insert
a prosthesis was higher when ejection fraction was 25% or lower or end
diastolic diameter was 60 mm or higher.
3.1. Survival
Six patients died early after surgery, 2 (1.2%) within and other 4
(2.4%) after 30 days from surgery, but during the same admission, for
a global in-hospital mortality of 3.6%, similar in both groups (5 cases,
3.7%, inMVr group and 1 case, 3.1%, inMVPI group, p= 0.8743). Causes
of death were low output syndrome, pulmonary infection and sepsis, 2
cases each. After a mean follow up of 8 ± 4 months 11 more patients
died (9 inMVr and 2 inMVPI groups), for cardiac (n= 4) e non-cardiacTable 2
Surgical details.
MVr (n = 135) MVPI (n = 32) p
SMB40™ 115 (85.2%) – na
Physioring 20 (14.8%) – na
Tissue valve – 26 (81.2%) na
Mechanical prosthesis – 6 (18.8%) na
CABG 132 (97.8%) 31 (96.9%) 0.7639
LV surgical remodeling 33 (24.4%) 13 (40.6%) 0.0655
TV surgery 53 (38.2%) 22 (68.8%) 0.0026
CPB time (min) 132 ± 33 142 ± 32 0.1231
Cross clamping (min) 103 ± 28 115 ± 31 0.0342
Chordal cutting 9 (5.4%) – na
AL augmentation 3 (2.2%) – na
Legend. MVr, mitral valve repair; MVPI, mitral valve prosthesis insertion; na, not applica-
ble; CABG, coronary artery bypass grafting; LV, left ventricle; TV, tricuspid valve; CPB, car-
diopulmonary bypass; AL, anterior leaﬂet.(n= 7) causes. Three-year freedom from death any cause was 87± 3%,
similar in both groups, 88 ± 4 in MVr group and 86 ± 6 in MVPI group
(Fig. 1). Freedom from cardiac death was 91 ± 3%, without differences
between groups (92± 3 inMVr and 90±4 inMVPI group). No patients
were reoperated on formechanical problems (ring or bandor prosthesis
dehiscence) or for MR return.3.2. Functional results
The mean NYHA Class in the survivors was 1.5 ± 0.6, with only 3
patients in NYHA Class III or IV. Possibility to be alive and in NYHA
Class I or II was 82 ± 3.2, without differences between groups (83 ± 4
in MVr and 80 ± 5 in MVPI groups, Fig. 2).
MVPI was inserted into a regression Cox model but it was not an
independent variable for lower survival, freedom from cardiac death
and possibility to be alive and in NYHA Class I or II.3.3. Echocardiographic results
After a minimum of 4 months, 139 patients had an echocardio-
graphic evaluation (mean 13 ± 8), 111 in group MVr and 28 in group
MVPI. Table 3 shows the details. EF rose in both groups, whereas PAP,
LVEDD and LVESD reduced signiﬁcantly. MR grade was, in the follow-
up echocardiogram, signiﬁcantly reduced in both groups. MR grade
was, however, lower in the MVPI group (0.1 ± 0.2 versus 0.3 ± 0.3 in
MVr group, p = 0.0011). RV function improved signiﬁcantly in the
MVr group, whereas it remained unchanged in the MVPI group. RV
dysfunction was present in 7 preoperatively and in 9 at the follow-up,
with only 2 patients whomaintained had RV dysfunction preoperative-
ly and at follow-up.Fig. 1. Survival in the whole statistics (A) and in groups MVr (solid) and MVPI (dashed).
Fig. 2. Survival in NYHA Class I/II in thewhole statistics (A) and in groups MVr (solid) and
MVPI (dashed).
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echocardiographic results of the 119 patients who did not undergo
SVR. The results were similar to the global population.
4. Discussion
The main ﬁnding of this study is that, with proper indications and a
correct surgical technique, MV repair and MVPI are not antagonist, but
part of a strategy to treat CIMR. This disease has not a uniform pattern,
but can differ from patient to patient. For this reason choosing a single
technique for everyone can limit the efﬁcacy of surgical treatment.
The natural history of CIMR is not favorable. The presence of CIMR
after myocardial infarction has been demonstrated to be related to
lower survival [12,13] and higher incidence of congestive heart failure
[14]. The excessmortality was independent of both the EF and the func-
tional status [12]. CIMR left untreated after PCI [15] or when coronary
artery bypass graftingwas performed has also been shown to be follow-
ed by a worse long-term outcome, even if moderate or less [16].
There is general agreement that overreductive MV annuloplasty,
proposed by Bolling et al. [1] for ischemic and non-ischemic cardiomy-
opathies, is the technique of choice to correct CIMR. Even if the same
authors [17] were not able to demonstrate any beneﬁt in survival
when comparing treated and untreated patients, others [18,19] found,
in randomized trials, annuloplasty to improve the clinical status in
patients with moderate CIMR. Nevertheless, the evolution of MR after
surgical correction is not always favorable. Due to the intrinsic charac-
teristics of the disease, mostly related to ventricular events rather than
to MV pathology, residual or recurrent MR is constantly shown in the
follow-up of surgical series. CIMR in fact is a ventricular disease, because
the mechanism of closure of the MV is affected by displacement of e or
both papillary muscles. Consequences of these changes are regurgita-
tion of a different grade and deepening of the CD.Table 3
Echocardiographic follow up.
MVr (n = 111)
Pre Post
EF (%:mean ± SD) 32 ± 6 35 ± 8
LVEDD (mm:mean ± SD) 57 ± 7 53 ± 8
LVESD (mm:mean ± SD) 44 ± 8 41 ± 7
MR grade (1–4:mean ± SD) 2.5 ± 1.1 0.3 ± 0.6
PAPs (mm Hg:mean ± SD) 40 ± 16 34 ± 11
TDI (cm/s) 11.4 ± 1.2 11.8 ± 1.5
Gradient (mm Hg: mean ± SD) – 4 ± 2
Legend.MVr,mitral vavle repair;MVPI,mitral valve prosthesis insertion; SD, standarddeviation
end systolic diameter; MR, mitral regurgitation; PAPs, pulmonary artery pressure systolic; TDI,In our opinion, there is a cutoff point, at which conservative tech-
niques do not pay in the mid or long term. Our group [2] proposed a
CD N10 mm as a surrogate for the ventricular modiﬁcations that could
sustain MR return. In this study, even if patients who underwent
MV prosthesis insertion were sicker and showed worse preoperative
echocardiographic ﬁndings, early mortality was similar than that in
the MV repair group, with similar 3-year survival. This ﬁnding is coher-
ent with the literature. Studies on this subject, even relatively few
[3–6,8,20–22], all report similar early and late survival. The most recent
report is the ISTMIR study [5], which included 1006 patients (298 MV
replacement and 708 MV repair). In propensity matched patients
early mortality was 3.3% in repair vs 5.3% in replacement and 8-year
survival was 81.6% ± 2.8% and 79.6% ± 4.8% (p = 0.42). On the other
side, different results were reported by De Bonis et al. [23] in a different
population, made of 132 patients with dilated cardiomyopathy, mostly
ischemic. In the replacement group early mortality was signiﬁcantly
higher (12.7% vs 2.3%, p = 0.03) and the 2.5-year survival was signiﬁ-
cantly lower (73 ± 7.9% vs 92 ± 3.2%, p = 0.02).
Another important ﬁnding in our study is the lower incidence of MR
in the MVPI group if compared with the MVr group. This is a common
ﬁnding in other surgical series as well. Al-Radi et al. [22] reported an in-
cidence of reoperations of 14% in the repair group due to failure of the
repair and of 3% in the replacement group (p = 0.003). In the experi-
ence of Magne et al. [3], at predischarge examination, incidence of
persistent moderate MR was higher in the repair group (18% vs 4%,
p b 0.0001). Chan et al. [4] reported that freedom from recurrent
MR moderate or more was 85.7 ± 13.2% for replacement and 41.4 ±
14.8% after repair, p = 0.04. Finally, the ISTMIR study [5] reported an
actual freedom from valve-related reoperation of 71.3 ± 3.5% versus
85.5 ± 3.9 in MV repair and MV replacement, respectively (p b .001).
In our experience, the grade of persistent/recurrent MR in MVr group
was low (0.3 ± 0.3), but still higher than in patients in the MVPI
group (0.1 ± 0.2, p = 0.018).
It is noteworthy that EF improved in both groups and LVESD reduced
as well. Even if our experience includes patients with low mean EF,
elimination of the MR was beneﬁcial in terms of improvement of both
functional Class and ventricular performance. Even if the concept that
CIMR is a ventricular disease is widely accepted, it was not clear if
CIMR, as it started when LV function was already compromised, was a
variable to cause further worsening or a marker of worsening heart
failure. Even if this debate is not over, there are experimental evidences
that addition of amoderateMR (created bymeans of a shunt interposed
between the LV and the left atrium) after ligation of the mid LAD in
dogs, caused the infarcted hearts to become more dilated with lower
EF than the controls, where, after LAD ligation, the shunt was not
created [24]. We think that CIMR has its own life and, if corrected, will
improve, if not survival, at least the functional Class [18,19].
Surgery on LV scar is an integral part of the treatment of CIMR. In our
opinion it is difﬁcult to separate patients where LV surgery is performed
by those where LV surgery is not performed. Even if the STICH trial
failed to show any beneﬁt in LV surgical remodeling, in our opinionMVPI (n = 28)
p Pre Post p
0.0018 26 ± 7 30 ± 4 0.0112
0.0001 63 ± 7 57 ± 9 0.0000
0.0033 49 ± 8 43 ± 9 0.0109
0.0000 3.5 ± 0.9 0.1 ± 0.2 0.0000
0.0013 51 ± 22 33 ± 12 0.0004
0.0293 11.9 ± 1.5 12.0 ± 1.2 0.7840
– – 5 ± 3 0.0360
; EF, ejection fraction; LVEDD, left ventricular enddiastolic diameter; LVESD, left ventricular
tissue doppler imaging.
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general, regardless of the presence or not of a scar of surgical interest.
On the other hand, other reports [25] underlined how a LV dimension
higher than 65 mm was related to a poor outcome. Then very likely
there is a limit to what can be done on the MV, at least to reverse
symptoms. We think that, to treat correctly CIMR, it is important to
have an openmind and not to address only themitral annulus. Evenmi-
tral regurgitation is generated by a ventricular event, there are a variety
of anatomic features which can be predominant from time to time,
needing different surgical approaches according to the speciﬁc ﬁndings.
5. Limitations of the study
This was a retrospective study, but it included all the patients who
underwent CIMR, independent of the location of the myocardial infarc-
tion, as it happens in the real world. The anatomic and functional as-
pects of the MV were different, just as are the functional consequences
of ventricular disease on the pathophysiology of the MV.
The follow-up was relatively short, but most of the adverse out-
comes after surgery for functional CIMR are seen in the early follow-
up. A large variety of surgical approaches were used on a relatively
small number of patients. Although this probably reﬂects the complex-
ity of this disease process and the lack of consensus regarding its treat-
ment, it also signiﬁcantly reduces our ability to make scientiﬁcally valid
conclusions from our data. Myocardial viability was not routinely
assessed and this may affect our conclusions on postoperative left
ventricular remodeling and functional mitral regurgitation recurrence.
6. Conclusions
CIMR is a complex disease which needs different surgical ap-
proaches, as goal of surgery is to eliminate or to reduce the regurgitation,
and not to repair the MV. There are many evidences that insertion of a
prosthesis, if compared with MV repair, has, at least, the same and,
sometimes, a better outcome in terms of MR return or persistency.
Nonetheless, surgeons are reluctant to accept a technique which is
considered suboptimal. However, we must be aware that this concept
descends from the experience in organicMV diseases and it is not appli-
cable to functional MR. In most of the cases MV can be repaired, adding
sometimes other procedures on the MV, but sometimes our choices
have to be different to achieve a better long term outcome.
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